Immunogenicity of SARS-CoV-2 mRNA vaccine in solid organ transplant recipients
| Autor: | Anna Nilsson, Jesper Rømhild Davidsen, Susan Olaf Lindvig, Rozeta Abazi, Mikael Kjær Poulsen, Janne Fuglsang Hansen, Claus Bistrup, Inge K. Holden, Isik Somuncu Johansen, Ulrik Stenz Justesen |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
COVID-19 Vaccines
Coronavirus disease 2019 (COVID-19) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immune response Immune system Immunogenicity Vaccine vaccine Internal Medicine Research Letter Medicine Humans RNA Messenger Covid‐19 Messenger RNA business.industry SARS-CoV-2 Immunogenicity COVID-19 Organ Transplantation Transplant Recipients Vaccination Regimen Immunology business Solid organ transplantation Covid-19 solid organ transplant recipient |
| Zdroj: | Holden, I K, Bistrup, C, Nilsson, A C, Hansen, J F, Abazi, R, Davidsen, J R, Poulsen, M K, Lindvig, S O, Justesen, U S & Johansen, I S 2021, ' Immunogenicity of SARS-CoV-2 mRNA vaccine in solid organ transplant recipients ', Journal of Internal Medicine, vol. 290, no. 6, pp. 1264-1267 . https://doi.org/10.1111/joim.13361 Journal of Internal Medicine |
| Popis: | Background It is currently not well described if a two-dose regimen of a Covid-19 vaccine is sufficient to elicit an immune response in SOT recipients. Results A total of 80 solid organ transplant (SOT) recipients completed a two-dose regimen with SARS-CoV-2 messenger RNA vaccine. Only 35.0% (n = 28) were able to mount a positive IgG immune response six weeks after the second dose of vaccine. Conclusion This emphasizes that SOT recipients need continued use of personal protective measures. Future studies need to closely examine the cellular immune response in patients with compromised antibody response to Covid-19 vaccination. This article is protected by copyright. All rights reserved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|